Regulation - Oncology

Filter

Current filters:

Oncology

Popular Filters

60 to 84 of 3435 results

GSK drops Phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic in NSCLC

GSK drops Phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic in NSCLC

02-04-2014

UK pharma major GlaxoSmithKline will stop its MAGRIT trial, a Phase III trial of its MAGE-A3 cancer immunotherapeuticin…

GlaxoSmithKlineMAGE-A3OncologyPharmaceuticalResearchUK

European generic drug makers sets out priorities for EU Trade Policy

European generic drug makers sets out priorities for EU Trade Policy

02-04-2014

European Generic Medicines Association (EGA) revealed this morning that its president, Nick Haggar, has…

EuropeGenericsPoliticsRegulationRest of the World

Synthon’s SYD985 may broaden target population of cancer patients

02-04-2014

Dutch generic drugs company Synthon Biopharmaceuticals has released the results of a head-to-head comparative…

KadcylaOncologyPharmaceuticalResearchRocheSYD985Synthon Biopharmaceuticals

US FDA approves Stallergenes’ allergy tablet Oralair

US FDA approves Stallergenes’ allergy tablet Oralair

02-04-2014

The US Food and Drug Administration has approved Oralair immunotherapy tablet from French allergen specialist…

ImmunologicalsOralairPharmaceuticalRegulationStallergenesUSA

MannKind’s diabetes drug Afrezza recommended by FDA advisory

02-04-2014

The US Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

AfrezzaDiabetesMannKindNorth AmericaPharmaceuticalRegulationUSA

Unanimous FDA advisory panel backing for Cubist’s Sivextro

Unanimous FDA advisory panel backing for Cubist’s Sivextro

02-04-2014

The US Food and Drug Administration’s Anti-Infective Drugs Advisory Committee on Monday voted unanimously…

Antibiotics and Infectious diseasesCubist PharmaceuticalsNorth AmericaPharmaceuticalRegulationSivextrotedizolidUSA

FDA advisory unanimously recommends Durata’s Dalvance

FDA advisory unanimously recommends Durata’s Dalvance

01-04-2014

The US Food and Drug Anti-Infective Drugs Advisory Committee voted 12 to 0 that Durata Therapeutics’…

Antibiotics and Infectious diseasesDalvanceDermatologicalsDurata TherapeuticsNorth AmericaPharmaceuticalRegulationUSA

Pancreatic cancer drug market in 6 major markets to see CAGR of 25% to 2017

Pancreatic cancer drug market in 6 major markets to see CAGR of 25% to 2017

01-04-2014

The global pancreatic cancer treatment market value in the six major countries (6MM: the USA, France,…

AbraxaneBiotechnologyCelgeneEuropeMarkets & MarketingOncologyUSA

Janssen files new NDA for combination HIV drug containing darunavir

Janssen files new NDA for combination HIV drug containing darunavir

01-04-2014

US health care giant Johnson & Johnson’s Europe-based subsidiary Janssen has submitted a New Drug Application…

Anti-viralsDarunavirJanssenPharmaceuticalPrezistaRegulationUSA

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

01-04-2014

The Pharma Letter interviewed chief executive Dr Thomas Taapken about Epigenomics’ lead product, increasing…

BiotechnologyEpi proColonEpigenomicsGermanyInterviewsOncology

Fairjourney Biologics signs agreement to develop therapeutic antibodies for heparanase

01-04-2014

Portuguese antibody solutions company Fairjourney Biologics has signed a research and option agreement…

BiotechnologyOncologyPortugalResearch

US FTC releases 2013 highlights, including action against Actavis and Mylan

US FTC releases 2013 highlights, including action against Actavis and Mylan

01-04-2014

The US Federal Trade Commission chairwoman Edith Ramirez has released the agency’s 2013 Annual Highlights,…

ActavisMylan LaboratoriesPharmaceuticalRegulationUSA

Otsuka acquires certain Dacogen and E7727 rights from Eisai

01-04-2014

Otsuka Pharmaceutical has reached an agreement with the US subsidiary of fellow Japanese drugmaker Eisai…

DacogenE7727EisaiLicensingOncologyOtsukaPharmaceutical

Lilly's Alimta patent upheld through 2022

Lilly's Alimta patent upheld through 2022

01-04-2014

US pharma major Eli Lilly says that the US District Court for the Southern District of Indiana has ruled…

AlimtaEli LillyLegalNorth AmericaOncologyPatentsPharmaceuticalTeva Pharmaceutical IndustriesUSA

Bayer’s Adempas gains EU clearance for two forms of PAH

Bayer’s Adempas gains EU clearance for two forms of PAH

31-03-2014

Following a previous positive opinion from the European Medicines Agency’s advisory committee, the…

AdempasBayerEuropePharmaceuticalRegulationRespiratory and Pulmonary

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

31-03-2014

UK pharma major GlaxoSmithKline has withdrawn its application to the European Medicines Agency for a…

GlaxoSmithKlineOncologyPharmaceuticalRegulationUKVotrientWomen's Health

Clinigen gains rights to SpePharm’s Savene

Clinigen gains rights to SpePharm’s Savene

31-03-2014

The UK’s specialty pharma firm Clinigen Group says it has acquired rights to Savene (dexrazoxane) from…

Clinigen GroupGlobalLicensingNorgineOncologyPharmaceuticalSaveneSpePharma

Tiziana Pharma plans listing via reverse takeover

Tiziana Pharma plans listing via reverse takeover

31-03-2014

Tiziana Pharma, a recently-established UK biotech company that has licensed technology for a potential…

BiotechnologyMergers & AcquisitionsOncologyTiziana

EU approval for Dainippon Sumitomo and Takeda’s Latuda

EU approval for Dainippon Sumitomo and Takeda’s Latuda

28-03-2014

Japanese drug majors Dainippon Sumitomo Pharma and Takeda Pharmaceutical have received European Commission…

Dainippon Sumitomo PharmaEuropeLatudaNeurologicalPharmaceuticalRegulationSunovionTakeda Pharmaceuticals

US FDA advisory panel votes against approval of Novartis’ AHF drug

US FDA advisory panel votes against approval of Novartis’ AHF drug

28-03-2014

The US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee yesterday voted…

Cardio-vascularNorth AmericaNovartisPharmaceuticalReasanzRegulationserelaxinUSA

Alimera resubmits NDA for Iluvien

Alimera resubmits NDA for Iluvien

27-03-2014

US ophthalmic pharma specialist Alimera Sciences has resubmitted its New Drug Application for Iluvien…

AlimeraAlimera SciencesIluvienOphthalmicsPharmaceuticalRegulationUSA

60 to 84 of 3435 results

Company Spotlight

Fibrotech

Fibrotech

Back to top